Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today's Pharmaceutical Executive Daily, Cellectis discontinues its allogeneic CAR-T programs to pivot toward in vivo gene editing with two new lipid nanoparticle candidates targeting cardiometabolic disease, Novo Nordisk rebrands as simply "Novo" with a new tagline and cultural framework ahead of its Capital Markets Day, and Wendy Short Bartie, executive vice president and chief corporate affairs officer at Bristol Myers Squibb, speaks with Pharmaceutical Executive on why reputation is a company's strongest currency.
Cellectis announces a board-approved strategic transformation, discontinuing its lasme-cel and eti-cel allogeneic CAR-T programs driven by improved frontline regimens and emerging bispecific antibodies. The company is redirecting its platform toward in vivo gene editing, advancing .Heal-101, an APOC3-targeting base editor for severe hypertriglyceridemia that achieves roughly 55% on-site editing and cuts triglycerides by up to 68% in preclinical models, and .Heal-201, a PCSK9-targeting epigenetic modulator that reduces PCSK9 by more than 90% in humanized mouse models.
Novo Nordisk rebrands as simply "Novo," introducing the tagline "Lasting health starts now" and a new cultural framework called The Novo Way, while Novo Nordisk A/S remains the formal legal entity. Chief executive officer Mike Doustdar says health care must become more responsive, relevant, and easier to fit into everyday life, as the company sharpens its competitive position amid intensifying competition in obesity and diabetes care. Novo plans to detail the strategy further at its Capital Markets Day in London on September 21.
Finally, Pharmaceutical Executive speaks with Wendy Short Bartie, executive vice president and chief corporate affairs officer at Bristol Myers Squibb, on why she views reputation as a company's strongest currency, earned through transparent decision-making and accountability rather than manufactured messaging. Short Bartie, a former public defender who rose through BMS's hematology and oncology commercial ranks, points to the company reaching 14 million patients globally and donating $174 million through corporate giving in 2025 as evidence of reputation built through action. She argues that trust directly shapes a company's ability to operate, innovate, and grow, and that it must be spent wisely once earned.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
